Dolutegravir Use Over 48 Weeks Is Not Associated with Worsening Insulin Resistance and Pancreatic Beta Cell Function in a Cohort of HIV-Infected Ugandan Adults
Roles
Author
Document Type
Article
Publication Date
1-1-2023
Publication Title
AIDS Research and Therapy
DOI
10.1186/s12981-023-00564-6
Recommended Citation
Mulindwa, F., Castelnuovo, B., Brusselaers, N., Nabwana, M., Bollinger, R., Buzibye, A., Agnes Odongpiny, E. L., Kiguba, R., & Schwarz, J. (2023). Dolutegravir Use Over 48 Weeks Is Not Associated with Worsening Insulin Resistance and Pancreatic Beta Cell Function in a Cohort of HIV-Infected Ugandan Adults. AIDS Research and Therapy, 20 (1). https://doi.org/10.1186/s12981-023-00564-6
